Humasis Co

Humasis Co Free Cash Flow

The Free Cash Flow (FCF) of Humasis Co (205470.KQ) as of Nov 10, 2026 is 9.70 B KRW. In the previous year, Free Cash Flow (FCF) was 28.99 B KRW — a change of -66.53% (lower).

Free Cash Flow

9.70 BKRW

YoY

-66.53%

Last updated:

Free Cash Flow (FCF) of Humasis Co is 2025 9.70 B KRW. Free Cash Flow (FCF) of Humasis Co was 2024 28.99 B KRW. It decreases by -66.53% lower compared to the previous year.

The Humasis Co Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2018
-1.74 B KRW
Jan 1, 2019
-2.21 B KRW
Jan 1, 2020
-783.18 M KRW
Jan 1, 2021
186.91 B KRW
Jan 1, 2022
157.96 B KRW
Jan 1, 2023
-78.80 B KRW
Jan 1, 2024
28.99 B KRW
Jan 1, 2025
9.70 B KRW
The Humasis Co Free Cash Flow history
YEARFree Cash FlowYoY
9.70 BKRW-66.53%
28.99 BKRW-136.79%
-78.80 BKRW-149.88%
157.96 BKRW-15.49%
186.91 BKRW-23,965.38%
-783.18 MKRW-64.52%
-2.21 BKRW+27.06%
-1.74 BKRW-58.77%
-4.21 BKRW-2,888.84%
151.11 MKRW-5.80%
160.42 MKRW-319.95%
-72.93 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Free Cash Flow (FCF) of Humasis Co is 9.70 B KRW in 2025.

Free Cash Flow (FCF) of Humasis Co changed from 28.99 B KRW to 9.70 B KRW, representing a -66.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Humasis Co

All Key Metrics — Humasis Co